Events

Infosession 'Strategic Goods Control department' (dCSG) on defence-related goods
OCT
Tue
07
10:00 - 11:30

Starts in 4 months from now

Location

Online

Programmes
Security Digital, Industry & Space Digital Europe Cybersecurity Defence EDF NATO-EDA

The Strategic Goods Control department is again organising training courses so you can become acquainted with the subject matter.

There will be an online session (10:00-11:30) on the basic training in defence-related goods on Tuesday 7 October 2025.

This session is part of a series of 3 sessions. The other two taking place on Tuesday 25 March and Tuesday 24 June (each time from 10:00 AM to 11:30 AM).

More info on the website of dCSG.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.